Review Article

Fak 和 Fak 抑制剂的新见解

卷 28, 期 17, 2021

发表于: 03 November, 2020

页: [3318 - 3338] 页: 21

弟呕挨: 10.2174/0929867327666201103162239

价格: $65

摘要

背景:黏附斑激酶(Focal adhesion kinase, Fak)是一种细胞质蛋白酪氨酸激酶,在不同的实体癌中过表达和激活;它在转移形成、细胞迁移、侵袭和血管生成中发挥了重要作用,因此被认为是癌症治疗的潜在靶点,特别是在转移阶段。近年来,不同的研究强调了新的Fak抑制剂作为潜在抗癌药物的重要性,但其他研究证明了其在与心脏功能或病毒感染相关的不同病理中的作用。 方法:一项广泛的文献研究(104篇参考文献)已经完成了Fak的结构,它在肿瘤发展中的重要性,但也在目前正在研究的其他病理中。因此,目前正在进行临床研究的化合物使用适当的数据库进行处理。最后,对目前临床前研究的主要化学支架进行了分析,重点分析了其分子结构和活性结构关系(SAR)。 结果:目前,只有少数可逆atp竞争抑制剂正在进行临床前研究和临床试验。其他化合物,与不同的化学支架,研究获得更活跃和选择性的Fak抑制剂。这篇综述综述了Fak在癌症和其他病理中的不同功能;今天的临床试验化合物和最近的化学支架(也包括在专利)给出了最有趣的结果进行了研究。此外,还报道了PROTAC分子。 结论:尽管已经从Fak抑制剂和其他不同的抗癌药物之间的关联中获得了有希望的信息,但所有报道的结果表明,需要进行更多的研究来设计和合成新的选择性和更活性的化合物。此外,在核水平和非癌细胞中,其他重要的作用被证明,使这种蛋白质成为药物化学中越来越重要的靶点。

关键词: 病灶粘附激酶,Fak抑制剂,转移,癌症治疗,临床试验,PROTACS

[1]
Schaller, M.D.; Parsons, J.T. Focal adhesion kinase: an integrin-linked protein tyrosine kinase. Trends Cell Biol., 1993, 3(8), 258-262.[http://dx.doi.org/10.1016/0962-8924(93)90053-4] [PMID: 14731743]
[2]
Schlaepfer, D.D.; Hanks, S.K.; Hunter, T.; van der Geer, P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 1994, 372(6508), 786-791.[http://dx.doi.org/10.1038/372786a0] [PMID: 7997267]
[3]
Schaller, M.D. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J. Cell Sci., 2010, 123(Pt 7), 1007-1013.[http://dx.doi.org/10.1242/jcs.045112] [PMID: 20332118]
[4]
Parsons, J.T.; Slack-Davis, J.; Tilghman, R.; Roberts, W.G. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin. Cancer Res., 2008, 14(3), 627-632.[http://dx.doi.org/10.1158/1078-0432.CCR-07-2220] [PMID: 18245520]
[5]
Shanthi, E.; Krishna, M.H.; Arunesh, G.M.; Venkateswara Reddy, K.; Sooriya Kumar, J.; Viswanadhan, V.N. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin. Ther. Pat., 2014, 24(10), 1077-1100.[http://dx.doi.org/10.1517/13543776.2014.948845] [PMID: 25113248]
[6]
Parsons, J.T. Focal adhesion kinase: the first ten years. J. Cell Sci., 2003, 116(Pt 8), 1409-1416.[http://dx.doi.org/10.1242/jcs.00373] [PMID: 12640026]
[7]
Guan, J.L.; Trevithick, J.E.; Hynes, R.O. Fibronectin/integrin interaction induces tyrosine phosphorylation of a 120-kDa protein. Cell Regul., 1991, 2(11), 951-964.[http://dx.doi.org/10.1091/mbc.2.11.951] [PMID: 1725602]
[8]
Schwock, J.; Dhani, N.; Hedley, D.W. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin. Ther. Targets, 2010, 14(1), 77-94.[http://dx.doi.org/10.1517/14728220903460340] [PMID: 20001212]
[9]
Lv, P.C.; Jiang, A.Q.; Zhang, W.M.; Zhu, H.L. FAK inhibitors in Cancer, a patent review. Expert Opin. Ther. Pat., 2018, 28(2), 139-145.[http://dx.doi.org/10.1080/13543776.2018.1414183] [PMID: 29210300]
[10]
Cary, L.A.; Guan, J.L. Focal adhesion kinase in integrin-mediated signaling. Front. Biosci., 1999, 4(1-3)[http://dx.doi.org/10.2741/Cary] [PMID: 9889179]
[11]
Reiske, H.R.; Zhao, J.; Han, D.C.; Cooper, L.A.; Guan, J.L. Analysis of FAK-associated signaling pathways in the regulation of cell cycle progression. FEBS Lett., 2000, 486(3), 275-280.[http://dx.doi.org/10.1016/S0014-5793(00)02295-X] [PMID: 11119718]
[12]
McLean, G.W.; Carragher, N.O.; Avizienyte, E.; Evans, J.; Brunton, V.G.; Frame, M.C. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat. Rev. Cancer, 2005, 5(7), 505-515.[http://dx.doi.org/10.1038/nrc1647] [PMID: 16069815]
[13]
Golubovskaya, V.M.; Conway-Dorsey, K.; Edmiston, S.N.; Tse, C.K.; Lark, A.A.; Livasy, C.A.; Moore, D.; Millikan, R.C.; Cance, W.G. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int. J. Cancer, 2009, 125(7), 1735-1738.[http://dx.doi.org/10.1002/ijc.24486] [PMID: 19521985]
[14]
Lim, S.T.; Chen, X.L.; Lim, Y.; Hanson, D.A.; Vo, T.T.; Howerton, K.; Larocque, N.; Fisher, S.J.; Schlaepfer, D.D.; Ilic, D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell, 2008, 29(1), 9-22.[http://dx.doi.org/10.1016/j.molcel.2007.11.031] [PMID: 18206965]
[15]
Sulzmaier, F.J.; Jean, C.; Schlaepfer, D.D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer, 2014, 14(9), 598-610.[http://dx.doi.org/10.1038/nrc3792] [PMID: 25098269]
[16]
Goode, E.L.; Chenevix-Trench, G.; Song, H.; Ramus, S.J.; Notaridou, M.; Lawrenson, K.; Widschwendter, M.; Vierkant, R.A.; Larson, M.C.; Kjaer, S.K.; Birrer, M.J.; Berchuck, A.; Schildkraut, J.; Tomlinson, I.; Kiemeney, L.A.; Cook, L.S.; Gronwald, J.; Garcia-Closas, M.; Gore, M.E.; Campbell, I.; Whittemore, A.S.; Sutphen, R.; Phelan, C.; Anton-Culver, H.; Pearce, C.L.; Lambrechts, D.; Rossing, M.A.; Chang-Claude, J.; Moysich, K.B.; Goodman, M.T.; Dörk, T.; Nevanlinna, H.; Ness, R.B.; Rafnar, T.; Hogdall, C.; Hogdall, E.; Fridley, B.L.; Cunningham, J.M.; Sieh, W.; McGuire, V.; Godwin, A.K.; Cramer, D.W.; Hernandez, D.; Levine, D.; Lu, K.; Iversen, E.S.; Palmieri, R.T.; Houlston, R.; van Altena, A.M.; Aben, K.K.; Massuger, L.F.; Brooks-Wilson, A.; Kelemen, L.E.; Le, N.D.; Jakubowska, A.; Lubinski, J.; Medrek, K.; Stafford, A.; Easton, D.F.; Tyrer, J.; Bolton, K.L.; Harrington, P.; Eccles, D.; Chen, A.; Molina, A.N.; Davila, B.N.; Arango, H.; Tsai, Y.Y.; Chen, Z.; Risch, H.A.; McLaughlin, J.; Narod, S.A.; Ziogas, A.; Brewster, W.; Gentry-Maharaj, A.; Menon, U.; Wu, A.H.; Stram, D.O.; Pike, M.C.; Beesley, J.; Webb, P.M.; Chen, X.; Ekici, A.B.; Thiel, F.C.; Beckmann, M.W.; Yang, H.; Wentzensen, N.; Lissowska, J.; Fasching, P.A.; Despierre, E.; Amant, F.; Vergote, I.; Doherty, J.; Hein, R.; Wang-Gohrke, S.; Lurie, G.; Carney, M.E.; Thompson, P.J.; Runnebaum, I.; Hillemanns, P.; Dürst, M.; Antonenkova, N.; Bogdanova, N.; Leminen, A.; Butzow, R.; Heikkinen, T.; Stefansson, K.; Sulem, P.; Besenbacher, S.; Sellers, T.A.; Gayther, S.A.; Pharoah, P.D. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet., 2010, 42(10), 874-879.[http://dx.doi.org/10.1038/ng.668] [PMID: 20852632]
[17]
Corsi, J.M.; Rouer, E.; Girault, J.A.; Enslen, H. Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics, 2006, 7, 198.[http://dx.doi.org/10.1186/1471-2164-7-198] [PMID: 16889663]
[18]
Cance, W.G.; Golubovskaya, V.M. Focal adhesion kinase versus p53: apoptosis or survival? Sci. Signal., 2008, 1(20), pe22.[http://dx.doi.org/10.1126/stke.120pe22] [PMID: 18493017]
[19]
Walker, S.; Foster, F.; Wood, A.; Owens, T.; Brennan, K.; Streuli, C.H.; Gilmore, A.P. Oncogenic activation of FAK drives apoptosis suppression in a 3D-culture model of breast cancer initiation. Oncotarget, 2016, 7(43), 70336-70352.[http://dx.doi.org/10.18632/oncotarget.11856] [PMID: 27611942]
[20]
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474, 609-615.[http://dx.doi.org/10.1038/nature10166]
[21]
Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418), 61-70.[http://dx.doi.org/10.1038/nature11412] [PMID: 23000897]
[22]
Ward, K.K.; Tancioni, I.; Lawson, C.; Miller, N.L.G.; Jean, C.; Chen, X.L.; Uryu, S.; Kim, J.; Tarin, D.; Stupack, D.G.; Plaxe, S.C.; Schlaepfer, D.D. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin. Exp. Metastasis, 2013, 30(5), 579-594.[http://dx.doi.org/10.1007/s10585-012-9562-5] [PMID: 23275034]
[23]
Li, S.; Huang, X.; Zhang, D.; Huang, Q.; Pei, G.; Wang, L.; Jiang, W.; Hu, Q.; Tan, R.; Hua, Z.C. Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis. PLoS One, 2013, 8(11), e79336.[http://dx.doi.org/10.1371/journal.pone.0079336] [PMID: 24260201]
[24]
Lim, S.T. Nuclear FAK: a new mode of gene regulation from cellular adhesions. Mol. Cells, 2013, 36(1), 1-6.[http://dx.doi.org/10.1007/s10059-013-0139-1] [PMID: 23686429]
[25]
Zhou, J.; Yi, Q.; Tang, L. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review. J. Exp. Clin. Cancer Res., 2019, 38(1), 250.[http://dx.doi.org/10.1186/s13046-019-1265-1] [PMID: 31186061]
[26]
Lim, S.T.; Chen, X.L.; Tomar, A.; Miller, N.L.; Yoo, J.; Schlaepfer, D.D. Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation. J. Biol. Chem., 2010, 285(28), 21526-21536.[http://dx.doi.org/10.1074/jbc.M110.129999] [PMID: 20442405]
[27]
Sun, S.; Wu, H.J.; Guan, J.L. Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice. Sci. Rep., 2018, 8(1), 2550.[http://dx.doi.org/10.1038/s41598-018-20930-z] [PMID: 29416084]
[28]
Canel, M.; Byron, A.; Sims, A.H.; Cartier, J.; Patel, H.; Frame, M.C.; Brunton, V.G.; Serrels, B.; Serrels, A. Nuclear Fak and Runx1 cooperate to regulate IGFBP3, cell-cycle progression, and tumor growth. Cancer Res., 2017, 77(19), 5301-5312.[http://dx.doi.org/10.1158/0008-5472.CAN-17-0418] [PMID: 28807942]
[29]
Serrels, A.; Lund, T.; Serrels, B.; Byron, A.; McPherson, R.C.; von Kriegsheim, A.; Gómez-Cuadrado, L.; Canel, M.; Muir, M.; Ring, J.E.; Maniati, E.; Sims, A.H.; Pachter, J.A.; Brunton, V.G.; Gilbert, N.; Anderton, S.M.; Nibbs, R.J.B.; Frame, M.C. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell, 2015, 163(1), 160-173.[http://dx.doi.org/10.1016/j.cell.2015.09.001] [PMID: 26406376]
[30]
Ceccarelli, D.F.J.; Song, H.K.; Poy, F.; Schaller, M.D.; Eck, M.J. Crystal structure of the FERM domain of focal adhesion kinase. J. Biol. Chem., 2006, 281(1), 252-259.[http://dx.doi.org/10.1074/jbc.M509188200] [PMID: 16221668]
[31]
Leu, T.H.; Maa, M.C. Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397. Oncogene, 2002, 21(46), 6992-7000.[http://dx.doi.org/10.1038/sj.onc.1205904] [PMID: 12370821]
[32]
van Nimwegen, M.J.; van de Water, B. Focal adhesion kinase: a potential target in cancer therapy. Biochem. Pharmacol., 2007, 73(5), 597-609.[http://dx.doi.org/10.1016/j.bcp.2006.08.011] [PMID: 16997283]
[33]
Mitra, S.K.; Schlaepfer, D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol., 2006, 18(5), 516-523.[http://dx.doi.org/10.1016/j.ceb.2006.08.011] [PMID: 16919435]
[34]
Jain, M.H.; Somani, R.R. Role of focal adhesion kinase inhibitors as anti-cancer agents. World J. Pharma. Res., 2016, 5(11), 1585-1602.[http://dx.doi.org/10.20959/wjpr201611-7367]
[35]
Schlaepfer, D.D.; Mitra, S.K.; Ilic, D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim. Biophys. Acta, 2004, 1692(2-3), 77-102.[http://dx.doi.org/10.1016/j.bbamcr.2004.04.008] [PMID: 15246681]
[36]
Canel, M.; Serrels, A.; Miller, D.; Timpson, P.; Serrels, B.; Frame, M.C.; Brunton, V.G. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res., 2010, 70(22), 9413-9422.[http://dx.doi.org/10.1158/0008-5472.CAN-10-1454] [PMID: 21045155]
[37]
Zhao, J.; Guan, J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev., 2009, 28(1-2), 35-49.[http://dx.doi.org/10.1007/s10555-008-9165-4] [PMID: 19169797]
[38]
Golubovskaya, V.M. Targeting focal adhesion kinase in cancer-part I. Anticancer. Agents Med. Chem., 2010, 10(10), 713.[http://dx.doi.org/10.2174/187152010794728693] [PMID: 21348852]
[39]
Kato, A.; Kato, K.; Miyazawa, H.; Kobayashi, H.; Noguchi, N.; Kawashiri, S. Focal adhesion kinase (Fak) overexpression and phosphorylation in oral squamous cell carcinoma and their clinicopathological significance. Pathol. Oncol. Res., 2020, 26(3), 1659-1667.[http://dx.doi.org/10.1007/s12253-019-00732-y] [PMID: 31522363]
[40]
Zhou, Y.; Shu, C.; Huang, Y. Fibronectin promotes cervical cancer tumorigenesis through activating FAK signaling pathway. J. Cell. Biochem., 2019, 120(7), 10988-10997.[http://dx.doi.org/10.1002/jcb.28282] [PMID: 30977220]
[41]
Fujii, T.; Koshikawa, K.; Nomoto, S.; Okochi, O.; Kaneko, T.; Inoue, S.; Yatabe, Y.; Takeda, S.; Nakao, A. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J. Hepatol., 2004, 41(1), 104-111.[http://dx.doi.org/10.1016/j.jhep.2004.03.029] [PMID: 15246215]
[42]
Chen, Y.; Li, Q.; Tu, K.; Wang, Y.; Wang, X.; Liu, D.; Chen, C.; Liu, D.; Yang, R.; Qiu, W.; Kang, N. Focal adhesion kinase promotes hepatic stellate cell activation by regulating plasma membrane localization of TGFβ receptor 2. Hepatol Commun, 2019, 4(2), 268-283.[http://dx.doi.org/10.1002/hep4.1452] [PMID: 32025610]
[43]
Zhang, J.; Hochwald, S.N. The role of FAK in tumor metabolism and therapy. Pharmacol. Ther., 2014, 142(2), 154-163.[http://dx.doi.org/10.1016/j.pharmthera.2013.12.003] [PMID: 24333503]
[44]
Golubovskaya, V.M.; Finch, R.; Kweh, F.; Massoll, N.A.; Campbell-Thompson, M.; Wallace, M.R.; Cance, W.G. p53 regulates FAK expression in human tumor cells. Mol. Carcinog., 2008, 47(5), 373-382.[http://dx.doi.org/10.1002/mc.20395] [PMID: 17999388]
[45]
Tavora, B.; Batista, S.; Reynolds, L.E.; Jadeja, S.; Robinson, S.; Kostourou, V.; Hart, I.; Fruttiger, M.; Parsons, M.; Hodivala-Dilke, K.M. Endothelial FAK is required for tumour angiogenesis. EMBO Mol. Med., 2010, 2(12), 516-528.[http://dx.doi.org/10.1002/emmm.201000106] [PMID: 21154724]
[46]
Lechertier, T.; Hodivala-Dilke, K. Focal adhesion kinase and tumour angiogenesis. J. Pathol., 2012, 226(2), 404-412.[http://dx.doi.org/10.1002/path.3018] [PMID: 21984450]
[47]
Chen, Q.; Yi, B.; Ma, J.; Ning, J.; Wu, L.; Ma, D.; Lu, K.; Gu, J. α2-adrenoreceptor modulated FAK pathway induced by dexmedetomidine attenuates pulmonary microvascular hyper-permeability following kidney injury. Oncotarget, 2016, 7(35), 55990-56001.[http://dx.doi.org/10.18632/oncotarget.10809] [PMID: 27463003]
[48]
Jean, C.; Chen, X.L.; Nam, J.O.; Tancioni, I.; Uryu, S.; Lawson, C.; Ward, K.K.; Walsh, C.T.; Miller, N.L.; Ghassemian, M.; Turowski, P.; Dejana, E.; Weis, S.; Cheresh, D.A.; Schlaepfer, D.D. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J. Cell Biol., 2014, 204(2), 247-263.[http://dx.doi.org/10.1083/jcb.201307067] [PMID: 24446483]
[49]
Xu, D.; Liu, T.; Lin, L.; Li, S.; Hang, X.; Sun, Y. Exposure to endosulfan increases endothelial permeability by transcellular and paracellular pathways in relation to cardiovascular diseases. Environ. Pollut., 2017, 223, 111-119.[http://dx.doi.org/10.1016/j.envpol.2016.12.051] [PMID: 28108160]
[50]
Hwang, J.S.; Eun, S.Y.; Ham, S.A.; Yoo, T.; Lee, W.J.; Paek, K.S.; Do, J.T.; Lim, D.S.; Seo, H.G. PPARδ modulates oxLDL-induced apoptosis of vascular smooth muscle cells through a TGF-β/FAK signaling axis. Int. J. Biochem. Cell Biol., 2015, 62, 54-61.[http://dx.doi.org/10.1016/j.biocel.2015.02.014] [PMID: 25732738]
[51]
Zheng, Y.; Lu, Z. Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle, 2009, 8(21), 3474-3479.[http://dx.doi.org/10.4161/cc.8.21.9846] [PMID: 19829089]
[52]
Bergmann, S.; Elbahesh, H. Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology, 2019, 534, 54-63.[http://dx.doi.org/10.1016/j.virol.2019.05.020] [PMID: 31176924]
[53]
Mohanty, P.; Bhatnagar, S. In silico screening to identify inhibitors of growth factor receptor 2-focal adhesion kinase interaction for therapeutic treatment of pathological cardiac hypertrophy. Assay Drug Dev. Technol., 2019, 17(2), 58-67.[http://dx.doi.org/10.1089/adt.2018.887] [PMID: 30869527]
[54]
Taneja, N.; Neininger, A.C.; Bersi, M.R.; David, M.W.; Burnette, D.T. Focal adhesion kinase regulates early steps of myofibrillogenesis in cardiomyocytes. Cell Biol. (Henderson NV), 2018, 1-25.[http://dx.doi.org/10.1101/261248]
[55]
Franchi, M.V.; Ruoss, S.; Valdivieso, P.; Mitchell, K.W.; Smith, K.; Atherton, P.J.; Narici, M.V.; Flück, M. Regional regulation of focal adhesion kinase after concentric and eccentric loading is related to remodelling of human skeletal muscle. Acta Physiol. (Oxf.), 2018, 223(3), e13056.[http://dx.doi.org/10.1111/apha.13056] [PMID: 29438584]
[56]
Mohanty, A.; Pharaon, R.R.; Nam, A.; Salgia, S.; Kulkarni, P.; Massarelli, E. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opin. Investig. Drugs, 2020, 29(4), 399-409.[http://dx.doi.org/10.1080/13543784.2020.1740680] [PMID: 32178538]
[57]
Cromm, P.M.; Samarasinghe, K.T.G.; Hines, J.; Crews, C.M. Addressing kinase-independent functions of Fak via PROTAC mediated degradation. J. Am. Chem. Soc., 2018, 140(49), 17019-17026.[http://dx.doi.org/10.1021/jacs.8b08008] [PMID: 30444612]
[58]
Gao, H.; Wu, Y.; Sun, Y.; Yang, Y.; Zhou, G.; Rao, Y. Design, synthesis, and evaluation of highly potent Fak-targeting PROTACs. ACS Med. Chem. Lett., 2019, 11(10), 1855-1862.[http://dx.doi.org/10.1021/acsmedchemlett.9b00372] [PMID: 33062164]
[59]
Avraham, H.; Park, S.Y.; Schinkmann, K.; Avraham, S. RAFTK/Pyk2-mediated cellular signalling. Cell. Signal., 2000, 12(3), 123-133.[http://dx.doi.org/10.1016/S0898-6568(99)00076-5] [PMID: 10704819]
[60]
Lev, S.; Moreno, H.; Martinez, R.; Canoll, P.; Peles, E.; Musacchio, J.M.; Plowman, G.D.; Rudy, B.; Schlessinger, J. Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature, 1995, 376(6543), 737-745.[http://dx.doi.org/10.1038/376737a0] [PMID: 7544443]
[61]
Duong, L.T.; Rodan, G.A. PYK2 is an adhesion kinase in macrophages, localized in podosomes and activated by beta(2)-integrin ligation. Cell Motil. Cytoskeleton, 2000, 47(3), 174-188.[http://dx.doi.org/10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N] [PMID: 11056520]
[62]
Klingbeil, C.K.; Hauck, C.R.; Hsia, D.A.; Jones, K.C.; Reider, S.R.; Schlaepfer, D.D. Targeting Pyk2 to β 1-integrin-containing focal contacts rescues fibronectin-stimulated signaling and haptotactic motility defects of focal adhesion kinase-null cells. J. Cell Biol., 2001, 152(1), 97-110.[http://dx.doi.org/10.1083/jcb.152.1.97] [PMID: 11149924]
[63]
Shen, T.; Guo, Q. Role of Pyk2 in human cancers. Med. Sci. Monit., 2018, 24, 8172-8182.[http://dx.doi.org/10.12659/MSM.913479] [PMID: 30425234]
[64]
Xing, L.; Rai, B.; Lunney, E.A. Scaffold mining of kinase hinge binders in crystal structure database. J. Comput. Aided Mol. Des., 2014, 28(1), 13-23.[http://dx.doi.org/10.1007/s10822-013-9700-4] [PMID: 24375079]
[65]
Song, Z.; Yang, Y.; Liu, Z.; Peng, X.; Guo, J.; Yang, X.; Wu, K.; Ai, J.; Ding, J.; Geng, M.; Zhang, A. Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases. J. Med. Chem., 2015, 58(1), 197-211.[http://dx.doi.org/10.1021/jm5005144] [PMID: 24785465]
[66]
Kath, J.C.; Luzzio, M.J. Pyrimidine derivatives for the treatment of abnormal cell growth their preparation and pharmaceutical compositions. Pfizer Inc. USA. WO2005111016, 2005.
[67]
Kath, J.C.; Luzzio, M.J. Preparation of diamino pyrimidines for the treatment of abnormal cell growth. Pfizer Inc. USA. US 20050256144, 2005.
[68]
Kath, J.C.; Luzzio, M.J. Preparation of pyrimidine derivatives for the treatment of abnormal cell growth USA. Pfizer Inc., US 20050256145, 2005.
[69]
Holmes, I.P.; Bergman, Y.; Lunniss, G.E.; Nikac, M.; Chol, N.; Hemley, C.F.; Walker, S.R.; Foitzik, R.C.; Ganame, D.; Lessene, R. Preparation of N-phenylpyrimidin-2-amines as selective Fak inhibitors. Cancer Ther. CRC US 20130022594, 2013.
[70]
Holmes, I.P.; Bergman, Y.; Lunniss, G.E.; Nikac, M.; Choi, N.; Hemley, C.F.; Walker, S.R.; Foitzik, R.C.; Ganame, D.; Lessene, R. Selective Fak inhibitors. Cancer Ther. CRC US 20130324546, 2015.
[71]
Schlaepfer, D. Method of promoting apoptosis and inhibiting cancer metastasis by administration focal adhesion kinase (FAK) inhibitor. Poniard Pharmac., Inc. USA. WO 2011019943, 2011.
[72]
Cance, W.G.; Pandey, R.K.; Kurenova, E.V.; Ethirajan, M. Kinase protein binding inhibitors. Health Research, Inc. USA. US 20150051245, 2015.
[73]
Cance, W.G.; Pandey, R.K.; Kurenova, E.V.; Ethirajan, M. Preparation of dimethylpyridinylalkyldiamine derivatives and analogs for use as kinase protein binding inhibitors. Roswell Park Cancer Institute, USA. WO 2013074517, 2013.
[74]
Lee, J.; Song, H.J.; Koh, J.S.; Lee, H.K.; Kim, Y.; Chang, S.; Kim, H.W.; Lim, S.H.; Choi, J.S.; Kim, J.H.; Kim, S.W. Preparation of kinase inhibitors for pharmaceutical applications. Genosco, Oscotec Inc., USA. WO 2011060295, 2011.
[75]
Lafrance, L.V.; Leber, J.D.; Li, M.; Verma, S.K. Preparation of benzimidazolecarboxamides as inhibitors of FAK for treatment of proliferative diseases. GlaxoSmithKline LLC, USA. WO 2010126922, 2010.
[76]
Chu, S.S.; Alegria, L.A.; Bender, S.L; Benedict, S. P.; Borchardt, A.J.; Kania, R.S.; Nambu, M.D.; Tempczyk-Russell, A.M.; Sarshar, S. Preparation of diaminothiazoles for inhibiting protein kinases. Agouron Pharmaceuticals, Inc., USA. Patent: WO 2000075120, 2000.
[77]
Van Camp, J.; Patel, J.R.; Swann, S. Preparation of benzodiazepinones as Fak kinase inhibitors for treatment of cancers. Abbott Laboratories, USA. WO 2012045194, 2012.
[78]
Alaoui-Jamali, M.A.; Bijian, K.; Tao, J. Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof. The Royal Institution for the Advancement of Learning/Mcgill University Can. and Ocean University of China., WO 2013059927, 2013.
[79]
Yin, Y.; Su, Y. Dithiocarbamates compounds serving as fak inhibitors. Beijing Xibo Pharmaceutical Research Co. CN 111072571, 2018.
[80]
Feger, D.; Klotzbuecher, A.; Kubbutat, M.; Horst, G.; Lingnau, A.; Schaechtele, C.; Totzke, F. Use of indolocarbazole imides as selective protein kinase inhibitors for treatment of hematological and solid tumors. KTB Tumorforschungsgesellschaft m.b.H., Germany., WO 2009047216, 2009.
[81]
Breslin, H. J.; Dorsey, B.; Gregory, R. Macrocyclic compounds as ALK, Fak and Jak2 inhibitors and their preparation and use for the treatment of ALK-Fak- and Jak2-mediated diseases. Cephalon, Inc., USA. WO 2012125603, 2012.
[82]
Adams, J.L.; Faitg, T.H.; Johnson, N.W.; Peng, X. Anilinopyridines as inhibitors of Fak. SmithKline Beecham Corporation, USA. WO 2009105498, 2009.
[83]
Harling, J.D.; Tinworth, C. Compounds for treating disorders associated with aberrant kinase activity by degrading said kinase. GlaxoSmithKline, UK. WO 2018033556, 2018.
[84]
Ding, Y.; Fei, Y.; Lu, B. Emerging new concepts of degrader technologies. Trends Pharmacol. Sci., 2020, 41(7), 464-474.[http://dx.doi.org/10.1016/j.tips.2020.04.005] [PMID: 32416934]
[85]
Jones, S.F.; Siu, L.L.; Bendell, J.C.; Cleary, J.M.; Razak, A.R.; Infante, J.R.; Pandya, S.S.; Bedard, P.L.; Pierce, K.J.; Houk, B.; Roberts, W.G.; Shreeve, S.M.; Shapiro, G.I. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest. New Drugs, 2015, 33(5), 1100-1107.[http://dx.doi.org/10.1007/s10637-015-0282-y] [PMID: 26334219]
[86]
Shimizu, T.; Fukuoka, K.; Takeda, M.; Iwasa, T.; Yoshida, T.; Horobin, J.; Keegan, M.; Vaickus, L.; Chavan, A.; Padval, M.; Nakagawa, K. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2016, 77(5), 997-1003.[http://dx.doi.org/10.1007/s00280-016-3010-1] [PMID: 27025608]
[87]
Su, Y.; Li, R.; Ning, X.; Lin, Z.; Zhao, X.; Zhou, J.; Liu, J.; Jin, Y.; Yin, Y. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. Eur. J. Med. Chem., 2019, 177, 32-46.[http://dx.doi.org/10.1016/j.ejmech.2019.05.048] [PMID: 31129452]
[88]
Luzzio, M. J.; Autry, C. L.; Bhattacharya, S. K.; Freeman-Cook, K.D.; Hayward, M. M.; Hulford, C. A.; Nelson, K. L.; Xiao, J.; Zhao, X. Preparation of sulfonyl amide derivatives for the treatment of abnormal cell growth. Pfizer Products Inc., USA. WO 2008129380, 2008.
[89]
Du, W.; Li, Y. Deuterated Defactinib compound and application. Hinova Pharmaceuticals Inc., Rep. China. WO 2019214587, 2019.
[90]
Roberts, W.G.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; Coleman, K.; Yao, L.; Martinez-Alsina, L.; Lorenzen, M.; Berliner, M.; Luzzio, M.; Patel, N.; Schmitt, E.; LaGreca, S.; Jani, J.; Wessel, M.; Marr, E.; Griffor, M.; Vajdos, F. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res., 2008, 68(6), 1935-1944.[http://dx.doi.org/10.1158/0008-5472.CAN-07-5155] [PMID: 18339875]
[91]
Zhao, X.; Sun, W.; Puszyk, W.M.; Wallet, S.; Hochwald, S.; Robertson, K.; Liu, C. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma. Tumour Biol., 2017, 39(5), 1010428317699120.[http://dx.doi.org/10.1177/1010428317699120] [PMID: 28459212]
[92]
Lederer, P.A.; Zhou, T.; Chen, W.; Epshtein, Y.; Wang, H.; Mathew, B.; Jacobson, J.R. Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase. Vascul. Pharmacol., 2018, 110, 16-23.[http://dx.doi.org/10.1016/j.vph.2018.06.017] [PMID: 29969688]
[93]
Howe, G.A.; Xiao, B.; Zhao, H.; Al-Zahrani, K.N.; Hasim, M.S.; Villeneuve, J.; Sekhon, H.S.; Goss, G.D.; Sabourin, L.A.; Dimitroulakos, J.; Addison, C.L. Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer. PLoS One, 2016, 11(3), e0150567.[http://dx.doi.org/10.1371/journal.pone.0150567] [PMID: 26962872]
[94]
Ott, G.R.; Cheng, M.; Learn, K.S.; Wagner, J.; Gingrich, D.E.; Lisko, J.G.; Curry, M.; Mesaros, E.F.; Ghose, A.K.; Quail, M.R.; Wan, W.; Lu, L.; Dobrzanski, P.; Albom, M.S.; Angeles, T.S.; Wells-Knecht, K.; Huang, Z.; Aimone, L.D.; Bruckheimer, E.; Anderson, N.; Friedman, J.; Fernandez, S.V.; Ator, M.A.; Ruggeri, B.A.; Dorsey, B.D. Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (Fak) and anaplastic lymphoma kinase (ALK). J. Med. Chem., 2016, 59(16), 7478-7496.[http://dx.doi.org/10.1021/acs.jmedchem.6b00487] [PMID: 27527804]
[95]
Brown, N.F.; Williams, M.; Arkenau, H.T.; Fleming, R.A.; Tolson, J.; Yan, L.; Zhang, J.; Singh, R.; Auger, K.R.; Lenox, L.; Cox, D.; Lewis, Y.; Plisson, C.; Searle, G.; Saleem, A.; Blagden, S.; Mulholland, P. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098. Neuro-oncol., 2018, 20(12), 1634-1642.[http://dx.doi.org/10.1093/neuonc/noy078] [PMID: 29788497]
[96]
Auger, K.R.; Smitheman, K.N.; Korenchuk, S.; McHugh, C.; Kruger, R.; Van Aller, G.S.; Smallwood, A.; Gontarek, R.R.; Faitg, T.; Johnson, N. 387 the focal adhesion kinase inhibitor GSK2256098: a potent and selective inhibitor for the treatment of cancer. Eur. J. Cancer, 2012, 48, 118.[http://dx.doi.org/10.1016/S0959-8049(12)72185-8]
[97]
Mak, G.; Soria, J.C.; Blagden, S.P.; Plummer, R.; Fleming, R.A.; Nebot, N.; Zhang, J.; Mazumdar, J.; Rogan, D.; Gazzah, A.; Rizzuto, I.; Greystoke, A.; Yan, L.; Tolson, J.; Auger, K.R.; Arkenau, H.T. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br. J. Cancer, 2019, 120(10), 975-981.[http://dx.doi.org/10.1038/s41416-019-0452-3] [PMID: 30992546]
[98]
Tiede, S.; Meyer-Schaller, N.; Kalathur, R.K.R.; Ivanek, R.; Fagiani, E.; Schmassmann, P.; Stillhard, P.; Häfliger, S.; Kraut, N.; Schweifer, N.; Waizenegger, I.C.; Bill, R.; Christofori, G. The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 2018, 7(9), 73.[http://dx.doi.org/10.1038/s41389-018-0083-1] [PMID: 30237500]
[99]
Verheijen, R.B.; van der Biessen, D.A.J.; Hotte, S.J.; Siu, L.L.; Spreafico, A.; de Jonge, M.J.A.; Pronk, L.C.; De Vos, F.Y.F.L.; Schnell, D.; Hirte, H.W.; Steeghs, N.; Lolkema, M.P. Randomized, open-label, crossover studies evaluating the effect of food and liquid formulation on the pharmacokinetics of the novel focal adhesion kinase (Fak) inhibitor BI 853520. Target. Oncol., 2019, 14(1), 67-74.[http://dx.doi.org/10.1007/s11523-018-00618-0] [PMID: 30742245]
[100]
Hirt, U.A.; Waizenegger, I.C.; Schweifer, N.; Haslinger, C.; Gerlach, D.; Braunger, J.; Weyer-Czernilofsky, U.; Stadtmüller, H.; Sapountzis, I.; Bader, G.; Zoephel, A.; Bister, B.; Baum, A.; Quant, J.; Kraut, N.; Garin-Chesa, P.; Adolf, G.R. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis, 2018, 7(2), 21.[http://dx.doi.org/10.1038/s41389-018-0032-z] [PMID: 29472531]
[101]
Ai, M.; Wang, C.; Tang, Z.; Liu, K.; Sun, X.; Ma, T.; Li, Y.; Ma, X.; Li, L.; Chen, L. Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines. Bioorg. Chem., 2020, 94, 103408.[http://dx.doi.org/10.1016/j.bioorg.2019.103408] [PMID: 31706682]
[102]
Liu, T.J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W.K. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo . Mol. Cancer Ther., 2007, 6(4), 1357-1367.[http://dx.doi.org/10.1158/1535-7163.MCT-06-0476] [PMID: 17431114]
[103]
Kurio, N.; Shimo, T.; Fukazawa, T.; Takaoka, M.; Okui, T.; Hassan, N.M.; Honami, T.; Hatakeyama, S.; Ikeda, M.; Naomoto, Y.; Sasaki, A. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo . Exp. Cell Res., 2011, 317(8), 1134-1146.[http://dx.doi.org/10.1016/j.yexcr.2011.02.008] [PMID: 21338601]
[104]
Lietha, D.; Eck, M.J. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One, 2008, 3(11), e3800.[http://dx.doi.org/10.1371/journal.pone.0003800] [PMID: 19030106]
[105]
Wu, F.; Xu, T.; He, G.; Ouyang, L.; Han, B.; Peng, C.; Song, X.; Xiang, M. Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking. Int. J. Mol. Sci., 2012, 13(12), 15668-15678.[http://dx.doi.org/10.3390/ijms131215668] [PMID: 23443087]
[106]
Moritake, H.; Saito, Y.; Sawa, D.; Sameshima, N.; Yamada, A.; Kinoshita, M.; Kamimura, S.; Konomoto, T.; Nunoi, H. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma. Cancer Med., 2019, 8(18), 7809-7821.[http://dx.doi.org/10.1002/cam4.2647] [PMID: 31692287]
[107]
Liu, H.; Wu, B.; Ge, Y.; Huang, J.; Song, S.; Wang, C.; Yao, J.; Liu, K.; Li, Y.; Li, Y.; Ma, X. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. Bioorg. Med. Chem., 2017, 25(24), 6313-6321.[http://dx.doi.org/10.1016/j.bmc.2017.09.041] [PMID: 29102081]
[108]
Wang, L.; Ai, M.; Yu, J.; Jin, L.; Wang, C.; Liu, Z.; Shu, X.; Tang, Z.; Liu, K.; Luo, H.; Guan, W.; Sun, X.; Ma, X. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells. Eur. J. Med. Chem., 2019, 172, 154-162.[http://dx.doi.org/10.1016/j.ejmech.2019.04.004] [PMID: 30978560]
[109]
Dao, P.; Jarray, R.; Le Coq, J.; Lietha, D.; Loukaci, A.; Lepelletier, Y.; Hadj-Slimane, R.; Garbay, C.; Raynaud, F.; Chen, H. Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Bioorg. Med. Chem. Lett., 2013, 23(16), 4552-4556.[http://dx.doi.org/10.1016/j.bmcl.2013.06.038] [PMID: 23845217]
[110]
Dao, P.; Jarray, R.; Smith, N.; Lepelletier, Y.; Le Coq, J.; Lietha, D.; Hadj-Slimane, R.; Herbeuval, J-P.; Garbay, C.; Raynaud, F.; Chen, H. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities. Cancer Lett., 2014, 348(1-2), 88-99.[http://dx.doi.org/10.1016/j.canlet.2014.03.007] [PMID: 24657306]
[111]
Dao, P.; Lietha, D.; Etheve-Quelquejeu, M.; Garbay, C.; Chen, H. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity. Bioorg. Med. Chem. Lett., 2017, 27(8), 1727-1730.[http://dx.doi.org/10.1016/j.bmcl.2017.02.072] [PMID: 28284808]
[112]
Dao, P.; Smith, N.; Tomkiewicz-Raulet, C.; Yen-Pon, E.; Camacho-Artacho, M.; Lietha, D.; Herbeuval, J.P.; Coumoul, X.; Garbay, C.; Chen, H. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity. J. Med. Chem., 2015, 58(1), 237-251.[http://dx.doi.org/10.1021/jm500784e] [PMID: 25180654]
[113]
Choi, H.S.; Wang, Z.; Richmond, W.; He, X.; Yang, K.; Jiang, T.; Sim, T.; Karanewsky, D.; Gu, X-J.; Zhou, V.; Liu, Y.; Ohmori, O.; Caldwell, J.; Gray, N.; He, Y. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett., 2006, 16(8), 2173-2176.[http://dx.doi.org/10.1016/j.bmcl.2006.01.053] [PMID: 16458503]
[114]
Wang, R.; Chen, Y.; Zhao, X.; Yu, S.; Yang, B.; Wu, T.; Guo, J.; Hao, C.; Zhao, D.; Cheng, M. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents. Eur. J. Med. Chem., 2019, 183, 111716.[http://dx.doi.org/10.1016/j.ejmech.2019.111716] [PMID: 31550660]
[115]
Wang, R.; Zhao, X.; Yu, S.; Chen, Y.; Cui, H.; Wu, T.; Hao, C.; Zhao, D.; Cheng, M. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study. Bioorg. Chem., 2020, 102, 104092.[http://dx.doi.org/10.1016/j.bioorg.2020.104092] [PMID: 32707280]
[116]
Wang, R.; Yu, S.; Zhao, X.; Chen, Y.; Yang, B.; Wu, T.; Hao, C.; Zhao, D.; Cheng, M. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Eur. J. Med. Chem., 2020, 188, 112024.[http://dx.doi.org/10.1016/j.ejmech.2019.112024] [PMID: 31923858]
[117]
Gütschow, M.; Eynde, J.J.V.; Jampilek, J.; Kang, C.; Mangoni, A.A.; Fossa, P.; Karaman, R.; Trabocchi, A.; Scott, P.J.H.; Reynisson, J.; Rapposelli, S.; Galdiero, S.; Winum, J.Y.; Brullo, C.; Prokai-Tatrai, K.; Sharma, A.K.; Schapira, M.; Azuma, Y.T.; Cerchia, L.; Spetea, M.; Torri, G.; Collina, S.; Geronikaki, A.; García-Sosa, A.T.; Vasconcelos, M.H.; Sousa, M.E.; Kosalec, I.; Tuccinardi, T.; Duarte, I.F.; Salvador, J.A.R.; Bertinaria, M.; Pellecchia, M.; Amato, J.; Rastelli, G.; Gomes, P.A.C.; Guedes, R.C.; Sabatier, J.M.; Estévez-Braun, A.; Pagano, B.; Mangani, S.; Ragno, R.; Kokotos, G.; Brindisi, M.; González, F.V.; Borges, F.; Miloso, M.; Rautio, J.; Muñoz-Torrero, D. Breakthroughs in medicinal chemistry: new targets and mechanisms, new drugs, new hopes-7. Molecules, 2020, 25(13), 2968.[http://dx.doi.org/10.3390/molecules25132968] [PMID: 32605268]
[118]
de Pins, B.; Montalban, E.; Vanhoutte, P.; Giralt, A.; Girault, J.A. The non-receptor tyrosine kinase Pyk2 modulates acute locomotor effects of cocaine in D1 receptor-expressing neurons of the nucleus accumbens. Sci. Rep., 2020, 10(1), 6619.[http://dx.doi.org/10.1038/s41598-020-63426-5] [PMID: 32313025]
[119]
Azizi, R.; Fallahian, F.; Aghaei, M.; Salemi, Z. Down-regulation of DDR1 induces apoptosis and inhibits EMT through phosphorylation of Pyk2/MKK7 in DU-145 and Lncap-FGC prostate cancer cell lines. Anticancer. Agents Med. Chem., 2020, 20(8), 1009-1016.[http://dx.doi.org/10.2174/1871520620666200410075558] [PMID: 32275493]
[120]
Chaudhary, P.K.; Han, J.S.; Jee, Y.; Lee, S.H.; Kim, S. Pyk2 downstream of G12/13 pathways regulates platelet shape change through RhoA/p160ROCK. Biochem. Biophys. Res. Commun., 2020, 526(3), 738-743.[http://dx.doi.org/10.1016/j.bbrc.2020.03.130] [PMID: 32265034]
[121]
Xiang, H.; Zhang, J.; Lin, C.; Zhang, L.; Liu, B.; Ouyang, L.; Ouyang, L. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm. Sin. B, 2020, 10(4), 569-581.[http://dx.doi.org/10.1016/j.apsb.2019.10.003] [PMID: 32322463]
[122]
Dawson, J.C.; Serrels, B.; Byron, A.; Muir, M.T.; Makda, A.; García-Muñoz, A.; von Kriegsheim, A.; Lietha, D.; Carragher, N.O.; Frame, M.C. A synergistic anticancer Fak and HDAC inhibitor combination discovered by a novel chemical-genetic high-content phenotypic screen. Mol. Cancer Ther., 2020, 19(2), 637-649.[http://dx.doi.org/10.1158/1535-7163.MCT-19-0330] [PMID: 31784455]
[123]
Hou, J.; Tan, Y.; Su, C.; Wang, T.; Gao, Z.; Song, D.; Zhao, J.; Liao, Y.; Liu, X.; Jiang, Y.; Feng, Q.; Wan, Z.; Yu, Y. Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways. Comput. Struct. Biotechnol. J., 2019, 18, 125-136.[http://dx.doi.org/10.1016/j.csbj.2019.12.010] [PMID: 31969973]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version397msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[21:45:34] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[21:45:34] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • warninglog[21:45:34] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[21:45:34] LOG.warning: strip_tags(): Passing null to parameter #1 ($string) of type string is depre...
  • warninglog[21:45:34] LOG.warning: strip_tags(): Passing null to parameter #1 ($string) of type string is depre...
  • warninglog[21:45:34] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (141ms)time
  • Application (256ms)time
  • 1 x Application (64.41%)
    256ms
    1 x Booting (35.58%)
    141ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    41 statements were executed, 4 of which were duplicates, 37 unique. Show only duplicated170ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('316245611','',1,1740347134,1740347134) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1740347134
      1.1msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('316245611','/article/111153/cn',1,1740347134,1740347134)
      150μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 316245611 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316245611) limit 1
      11.38msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 316245611
      • 1: 316245611
      • 2: 316245611
      • 3: 316245611
      • 4: 316245611
      • 5: 316245611
      • 6: 316245611
      • 7: 316245611
      • 8: 316245611
      • 9: 316245611
      • 10: 316245611
      • 11: 316245611
      • 12: 316245611
      • 13: 316245611
      • 14: 316245611
      • 15: 316245611
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=111153
      770μsalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 25 limit 1
      820μsalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 25
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and sj.journal_id!=25 group by `j`.`nid`) as `aggregate_table`
      1.35msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and sj.journal_id!=25 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.09msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      3.26msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      2.79msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '111153'
      900μsalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 111153
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '111153'
      5.16msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 111153
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '111153' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      1.85msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 111153
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      210μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      440μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 25 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      30.93msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 25 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      31.67msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 25 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      27.64msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 111153 limit 1
      250μsalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 111153
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 111153 and content_type = 'article' order by status desc limit 1
      350μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid article_nid,a.title article_title,j.title journal_title from content_by_diseases cd inner join article a on a.article_id=cd.content_id inner join journal j on j.journal_id=a.journal_id where cd.pid = 16 and cd.sub_disease_id = 487 and content_id!=111153 and cd.content_type = 'article' order by rand() limit 20
      22.5msalphaeurekaselec_live_10_06_2022Article.php#769
      Backtrace
      • 11. app/Models/Article.php:769
      • 12. app/Http/Controllers/ArticleController.php:2098
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 187564 limit 1
      260μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 187564
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      200μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'CMC' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      350μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: CMC
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '111153' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      600μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '10690' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      290μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '2916' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      260μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2916) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2916) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2916)
      4.29msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 10690) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 10690) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 10690)
      590μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 111153) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 111153) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 316245611 and j.to_ip >=316245611 )) and ((j.from_date <= 1740347134 and j.to_date >= 1740347134 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 111153)
      680μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '3318' and is_uploaded = 1 and issue_id = 10690 order by cast(first_page as SIGNED) desc limit 1
      460μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 3318
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '3338' and is_uploaded = 1 and issue_id = 10690 order by cast(first_page as SIGNED) asc limit 1
      360μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 3338
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'cn'
      160μsalphaeurekaselec_live_10_06_2022ArticleController.php#2486
      Bindings
      • 0: cn
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2486
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 2
      210μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 2
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2487
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `multilanguage_article` where (`language_id` = 2 and `article_id` = 111153)
      5.68msalphaeurekaselec_live_10_06_2022ArticleController.php#2488
      Bindings
      • 0: 2
      • 1: 111153
      Backtrace
      • 15. app/Http/Controllers/ArticleController.php:2488
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `keyword` from `multilanguage_keywords` where (`language_id` = 2 and `article_id` = 111153)
      2.48msalphaeurekaselec_live_10_06_2022ArticleController.php#2489
      Bindings
      • 0: 2
      • 1: 111153
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2489
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT_WS(' ',au.last_name, ', ', ifnull(au.initials,''), ' ', au.first_name) as authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs , `au`.*, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `multilanguage_authors` as `au` left join `multilanguage_author_affiliation` as `af` on `au`.`id` = `af`.`author_id` where `au`.`article_id` = 111153 group by `au`.`id` order by `au`.`article_id` asc, `au`.`sequence` asc
      3.82msalphaeurekaselec_live_10_06_2022MultiLangAuthor.php#30
      Bindings
      • 0: 111153
      Backtrace
      • 13. app/Models/MultiLangAuthor.php:30
      • 14. app/Http/Controllers/ArticleController.php:2493
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `multilanguage_journal`.`title` from `multilanguage_journal` where `multilanguage_journal`.`journal_id` = 25 and `language_id` = 2
      240μsalphaeurekaselec_live_10_06_2022ArticleController.php#2495
      Bindings
      • 0: 25
      • 1: 2
      Backtrace
      • 13. app/Http/Controllers/ArticleController.php:2495
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `id` from `multilanguage_article` where `article_id` = 111153 limit 1
      2.12msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 111153
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 25 and `b`.`banner_from_date` <= 1740347134 and `b`.`banner_to_date` >= 1740347134 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.15msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 25
      • 3: 1740347134
      • 4: 1740347134
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 25 and `b`.`banner_from_date` <= 1740347134 and `b`.`banner_to_date` >= 1740347134 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.4msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 25
      • 3: 1740347134
      • 4: 1740347134
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='3d793b02bce4c60230f30c4b03724ba7'
      260μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLangArticle
    2MultiLangArticle.php#?
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        8Q5D6blRNxMDiuuw41HOorKRBwQqChWqZAn473ZC
        uc_cart_id
        3d793b02bce4c60230f30c4b03724ba7
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/111153/cn" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/111153/cn
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:9 [ "cookie" => array:1 [ 0 => "wayfindertarget=eyJpdiI6ImczZDVUaGlQVjg5V0hpdmhxWW5rN3c9PSIsInZhbHVlIjoiU0JqMXAxMThZeVY3SGVvMk1rYVpxN2VmY0hUTGxRK05pTXFBSkNxSmZ6TT0iLCJtYWMiOiI0NzVjZDIwOTlmZTc5MjRiZTEyOTNiZTIxNGVkZjdjZmViYmVjMGU4NmI1NTQ5NDEzYmIzYmM1MGE4MWUxOWFhIiwidGFnIjoiIn0%3Dwayfindertarget=eyJpdiI6ImczZDVUaGlQVjg5V0hpdmhxWW5rN3c9PSIsInZhbHVlIjoiU0JqMXAxMThZeVY3SGVvMk1rYVpxN2VmY0hUTGxRK05pTXFBSkNxSmZ6TT0iLCJtYWMiOiI0NzVjZDIwOTlmZTc5" ] "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        0 of 0
        array:1 [ "wayfindertarget" => null ]
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Sun, 23 Feb 2025 21:45:34 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IkdHUDlqKzRkc1NBa0V6anl5eTZoY0E9PSIsInZhbHVlIjoiait1UlhFb2JTenhoRXhyY0NIYkROUWo2YlZvUXozYVVvMUJuZ0R4R1NWTDN4U0hDUTl4NTFkZDluVGZxelZrNE9NWW5sVHEvWFFNTE1oR1daYU1UcWk3V3JsbXdXZUNxOG9hNThFblZZZzQyOFhURGpwRVA1dnk0WXRvN01nVjUiLCJtYWMiOiIyNTY2OGNlY2FlZjI2NTQ1NWUyOTgyZWQ5MGZmMDdkNzRlMTQ1NDI1ZGUyOGUzMjllMmI3M2ZjZDllYzJhZTE0IiwidGFnIjoiIn0%3D; expires=Wed, 26 Feb 2025 09:45:34 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6IkdHUDlqKzRkc1NBa0V6anl5eTZoY0E9PSIsInZhbHVlIjoiait1UlhFb2JTenhoRXhyY0NIYkROUWo2YlZvUXozYVVvMUJuZ0R4R1NWTDN4U0hDUTl4NTFkZDluVGZxelZrNE9NWW5sV" 1 => "alphaeurekaselectnet_session=eyJpdiI6ImJFMG42K05vNFhGbUx6UnBpbjBQUnc9PSIsInZhbHVlIjoiN3RQM3p3dUZFaHQwMWo4WEsxcU5QTjB2TGFBQ2Z6TzlaWVFHTUl5a1ozQWJkMHo3QXJKWjZIVUJZbXF6L0dJSUQ4Q3VBTmhZREp2aFVHYzJ0NjN4UkZrQ3Z3Vkx3dU05K0pZUkdkNHVrT1BlNTdsdklUeG1OVXpNTE1mVGxIYTAiLCJtYWMiOiJmYTQ3ZmJkYjUyMTY1MTlhMGRhMDUyYzdkMzk5M2E4ZWFjZGI3ZGZiM2JhNWIwMGQyYmMwOTA3MzRiM2IzMDU0IiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6ImJFMG42K05vNFhGbUx6UnBpbjBQUnc9PSIsInZhbHVlIjoiN3RQM3p3dUZFaHQwMWo4WEsxcU5QTjB2TGFBQ2Z6TzlaWVFHTUl5a1ozQWJkMHo3QXJKWjZIVUJ" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IkdHUDlqKzRkc1NBa0V6anl5eTZoY0E9PSIsInZhbHVlIjoiait1UlhFb2JTenhoRXhyY0NIYkROUWo2YlZvUXozYVVvMUJuZ0R4R1NWTDN4U0hDUTl4NTFkZDluVGZxelZrNE9NWW5sVHEvWFFNTE1oR1daYU1UcWk3V3JsbXdXZUNxOG9hNThFblZZZzQyOFhURGpwRVA1dnk0WXRvN01nVjUiLCJtYWMiOiIyNTY2OGNlY2FlZjI2NTQ1NWUyOTgyZWQ5MGZmMDdkNzRlMTQ1NDI1ZGUyOGUzMjllMmI3M2ZjZDllYzJhZTE0IiwidGFnIjoiIn0%3D; expires=Wed, 26-Feb-2025 09:45:34 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6IkdHUDlqKzRkc1NBa0V6anl5eTZoY0E9PSIsInZhbHVlIjoiait1UlhFb2JTenhoRXhyY0NIYkROUWo2YlZvUXozYVVvMUJuZ0R4R1NWTDN4U0hDUTl4NTFkZDluVGZxelZrNE9NWW5sV" 1 => "alphaeurekaselectnet_session=eyJpdiI6ImJFMG42K05vNFhGbUx6UnBpbjBQUnc9PSIsInZhbHVlIjoiN3RQM3p3dUZFaHQwMWo4WEsxcU5QTjB2TGFBQ2Z6TzlaWVFHTUl5a1ozQWJkMHo3QXJKWjZIVUJZbXF6L0dJSUQ4Q3VBTmhZREp2aFVHYzJ0NjN4UkZrQ3Z3Vkx3dU05K0pZUkdkNHVrT1BlNTdsdklUeG1OVXpNTE1mVGxIYTAiLCJtYWMiOiJmYTQ3ZmJkYjUyMTY1MTlhMGRhMDUyYzdkMzk5M2E4ZWFjZGI3ZGZiM2JhNWIwMGQyYmMwOTA3MzRiM2IzMDU0IiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6ImJFMG42K05vNFhGbUx6UnBpbjBQUnc9PSIsInZhbHVlIjoiN3RQM3p3dUZFaHQwMWo4WEsxcU5QTjB2TGFBQ2Z6TzlaWVFHTUl5a1ozQWJkMHo3QXJKWjZIVUJ" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "8Q5D6blRNxMDiuuw41HOorKRBwQqChWqZAn473ZC" "uc_cart_id" => "3d793b02bce4c60230f30c4b03724ba7" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/111153/cn" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-23 21:45:34GET/article/111153/cn614413